Regeneron Pharmaceuticals (REGN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$827.72-1.87%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Regeneron grows sales about 12% a year with new drug launches. Profit margins stay strong near 78%. The company controls costs and tax rates well. FDA fast-track programs speed product approvals.
Disappointing trial data and legal setbacks could hurt future sales. Profit margins may fall below guidance. Revenue growth could slow below 7%.
The price is about 8% below our fair value near $733. Analysts expect roughly 12% revenue growth. Our fair value is 9% below the Street median, reflecting some caution.
Breaks if: Effective tax rate rises above 14% in FY26
Breaks if: Gross margin falls below 77% in FY26
Pipeline progress stalls or FDA fast-track designations are lost
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on consistent growth through product sales and a robust clinical pipeline. The current thesis state is intact, supported by strong recent financial results and management's commitment to advancing key products.
The market currently prices Regeneron as cheap compared to its peers, with a slight expectations gap. This suggests that investors may not fully anticipate the potential for continued growth in sales and product approvals.
Fundamentals are likely to remain strong, driven by management's focus on advancing their clinical pipeline and growing sales of key products like Dupixent and EYLEA HD. However, there is a moderate risk of missing earnings expectations, especially given the recent changes in the industry.
The most important moves since the prior daily snapshot.
Signal changed from 'favorable' to 'mild_favorable'.
Yes, our read has strengthened. The latest earnings beat supports the positive outlook. Guidance has also improved, reinforcing confidence in future performance. The FDA approval of Pasatru adds to growth potential. There are no new threats identified at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: YoY revenue growth falls below 7% in FY26
The long-term thesis hinges on the performance of Regeneron's clinical pipeline and the ability to maintain sales growth in key products. Additionally, external factors such as sector performance and overall economic conditions will play a critical role in shaping future outcomes.
Overall, Regeneron appears well-positioned for the next few years, but it will need to navigate potential risks and maintain its growth trajectory. Not investment advice.